Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Marc J. George"'
Publikováno v:
PLoS ONE, Vol 18, Iss 2 (2023)
Background Patient and public involvement (PPI) has growing impact on the design of clinical care and research studies. There remains underreporting of formal PPI events including views related to using digital tools. This study aimed to assess the f
Externí odkaz:
https://doaj.org/article/455fdf0561ee403083bfeaf6a0d49244
Publikováno v:
Clinical Infection in Practice, Vol 9, Iss , Pp 100059- (2021)
Background: Venous thrombo-embolism is now well-recognised as a common complication of severe COVID-19 disease. Arterial thrombosis has been less well recognised, although it is increasingly reported, mostly in the context of myocardial infarction an
Externí odkaz:
https://doaj.org/article/bd67fba96ada43bc8ee63b47e3d33183
Autor:
Marc J. George, Ola Kleveland, Jorge Garcia‐Hernandez, Jutta Palmen, Ruth Lovering, Rune Wiseth, Pål Aukrust, Jorgen Engmann, Jan Kristian Damås, Aroon D. Hingorani, Lars Gullestad, Juan P. Casas, Thor Ueland
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 9, Iss 12 (2020)
Background Interleukin 6 concentration is associated with myocardial injury, heart failure, and mortality after myocardial infarction. In the Norwegian tocilizumab non–ST‐segment–elevation myocardial infarction trial, the first randomized trial
Externí odkaz:
https://doaj.org/article/ffc25c005fd74317b0395faca6918f1e
Autor:
Savvina Prapiadou, Luka Živković, Barbara Thorand, Marc J. George, Sander W. van der Laan, Rainer Malik, Christian Herder, Wolfgang Koenig, Thor Ueland, Ola Kleveland, Pal Aukrust, Lars Gullestad, Jürgen Bernhagen, Gerard Pasterkamp, Annette Peters, Aroon D. Hingorani, Jonathan Rosand, Martin Dichgans, Christopher D. Anderson, Marios K. Georgakis
Publikováno v:
medRxiv
BackgroundGenetic and experimental studies support a causal involvement of interleukin-6 (IL-6) signaling in atheroprogression. While trials targeting IL-6 signaling are underway, any benefits must be balanced against an impaired host immune response
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ca641bd69d72d89bfa6fa1f1b643867
https://doi.org/10.1101/2023.03.24.23287543
https://doi.org/10.1101/2023.03.24.23287543
Publikováno v:
Clinical Infection in Practice
Clinical Infection in Practice, Vol 9, Iss, Pp 100059-(2021)
Clinical Infection in Practice, Vol 9, Iss, Pp 100059-(2021)
Highlights • Thrombosis associated with COVID-19 can occur at diverse sites. • Arterial as well as venous thrombosis can complicate COVID-19. • Thromboprophylaxis is advised for COVID-19 patients with thrombosis risk factors. • More evidence
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4135b2b251e0da3980572e2ab3f3e0ab
https://doi.org/10.1016/j.clinpr.2020.100059
https://doi.org/10.1016/j.clinpr.2020.100059
Autor:
Nur Hayati Jasmin, Angela Richard-Loendt, Kevin J. Woollard, Daniel J. Stuckey, Ana Garcia Diaz, Valerie Taylor Cummings, Mark F. Lythgoe, Tabitha Turner-Stokes, Marc J. George, Aroon D. Hingorani, Derek W. Gilroy, Francesca Launchbury
Publikováno v:
JACC: Basic to Translational Science, Vol 6, Iss 5, Pp 431-443 (2021)
Summary Interleukin (IL)-6 is an emerging therapeutic target in myocardial infarction (MI). IL-6 has 2 distinct signaling pathways: trans-signaling, which mediates inflammation, and classic signaling, which also has anti-inflammatory effects. The nov
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d50cdb217113807f986ddaebfe6d911c
https://pubmed.ncbi.nlm.nih.gov/34102669
https://pubmed.ncbi.nlm.nih.gov/34102669
Publikováno v:
British Journal of Clinical Pharmacology
Host immunity is required to clear SARS-CoV-2, and inability to clear the virus because of host or pathogen factors renders those infected at risk of poor outcomes. Estimates of those who are able to clear the virus with asymptomatic or paucisymptoma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe0563d06a439b40d310d8128198185f
https://pubmed.ncbi.nlm.nih.gov/32881064
https://pubmed.ncbi.nlm.nih.gov/32881064
Autor:
Ola Kleveland, Aroon D. Hingorani, Ruth C. Lovering, Rune Wiseth, Jutta Palmen, Juan P. Casas, Jan Kristian Damås, Jorgen Engmann, Marc J. George, Pål Aukrust, Lars Gullestad, Jorge Garcia-Hernandez, Thor Ueland
Publikováno v:
Journal of the American Heart Association
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Interleukin 6 concentration is associated with myocardial injury, heart failure, and mortality after myocardial infarction. In the Norwegian tocilizumab non–ST‐segment–elevation myocardial infarction trial, the first randomized trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a41be7f3bef3cd99b1f6abf428ee14e6
https://hdl.handle.net/11250/2726203
https://hdl.handle.net/11250/2726203
Autor:
Adrian J. Hobbs, Raymond J. MacAllister, Alexander A. Maini, Paul C. Norris, Marc J. George, Madhur P. Motwani, Charles N. Serhan, Alice Henderson, Derek W. Gilroy, Barbara White, Frances Bennett, Mark Tepper, Justine Newson
Publikováno v:
Clinical Pharmacology and Therapeutics
Anabasum is a synthetic analog of Δ8‐tetrahydrocannabinol (THC)‐11‐oic acid that in preclinical models of experimental inflammation exerts potent anti‐inflammatory actions with minimal central nervous system (CNS) cannabimimetic activity. He
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fdf455a7da6678eec85d10f90ab5c13f
https://pubmed.ncbi.nlm.nih.gov/29238967
https://pubmed.ncbi.nlm.nih.gov/29238967
Autor:
Madhur P, Motwani, Romain A, Colas, Marc J, George, Julia D, Flint, Jesmond, Dalli, Angela, Richard-Loendt, Roel Ph, De Maeyer, Charles N, Serhan, Derek W, Gilroy
Publikováno v:
JCI insight. 3(6)
While the treatment of inflammatory disorders is generally based on inhibiting factors that drive onset of inflammation, these therapies can compromise healing (NSAIDs) or dampen immunity against infections (biologics). In search of new antiinflammat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c2038a9dbe25b49afaeedf89729c72ab
https://pubmed.ncbi.nlm.nih.gov/29563331
https://pubmed.ncbi.nlm.nih.gov/29563331